Studies in the mouse model of oxygen-induced retinopathy (OIR) have shown that macrophage- induced angiogenesis has a critical role in pathological retinal neovascularization (RNV) but the mechanisms are not yet known. We propose to investigate expression/activity of the cholesterol metabolizing enzyme ACAT (acyl-Coenzyme A: cholesterol acyltransferase, also known as sterol O-acyltranserase) as a novel therapeutic target for RNV. There are two isoforms of ACAT: ACAT1 and ACAT2. ACAT1 is widely expressed and its upregulation in macrophages or macrophage/microglia has been implicated in atherosclerosis and Alzheimer's disease, respectively. ACAT2 is mainly expressed in the intestines and liver. We will focus on ACAT1 in this project. During ischemia/hypoxia, macrophages are exposed to increased levels of oxidized low density lipoprotein cholesterol (oxLDLc). Its internalization by the LDL receptor (LDLR) increases activity of ACAT1, which esterifies cholesterol to form cholesterol esters (CE). Increases in CE promote an inflammatory macrophage phenotype characterized by increased expression of the amplifier of inflammatory signaling TREM-1 (triggering receptor expressed in myeloid cells-1), MCSF (macrophage colony stimulating factor), VEGF and TNF?. Our preliminary studies in the mouse OIR model show marked increases in lipid accumulation, LDLR expression and CE formation in areas of RNV suggesting that dyslipidemia and ACAT activity play a key role in RNV. Furthermore, LDLR deletion or ACAT inhibition prevented RNV and decreased expression of TREM-1, MCSF and VEGF. Moreover, hypoxia treatment of macrophages in vitro significantly increased their expression of TREM-1, MCSF and VEGF. Based on these results our central hypothesis is that LDLc-induced increases in ACAT1 and CE formation drive macrophage activation and pathological RNV in the mouse model of OIR (Fig. 1).
Our aims will test this hypothesis by determining whether 1) Inhibition of ACAT1 prevents RNV in vivo, 2) Deletion of ACAT1 in myeloid derived cells prevents RNV in vivo and M? -induced angiogenesis in vitro.
This proposal seeks to develop a new molecular strategy to limit pathological retinal angiogenesis in blinding eye disease. ACAT1 (acyl-Coenzyme A: cholesterol acyltransferase 1) is a critical regulator/activator of cholesterol metabolism and a promotor of an inflammatory macrophage phenotype. The proposed studies are designed to use a highly specific ACAT1 inhibitor and ACAT1 deficient mice and cells to investigate the specific role of macrophage ACAT1 in pathological ocular angiogenesis and to define the underlying mechanisms.
